Literature DB >> 19424605

Association of gene polymorphisms with chronic kidney disease in high- or low-risk subjects defined by conventional risk factors.

Tetsuro Yoshida1, Kimihiko Kato, Kiyoshi Yokoi, Mitsutoshi Oguri, Sachiro Watanabe, Norifumi Metoki, Hidemi Yoshida, Kei Satoh, Yukitoshi Aoyagi, Yutaka Nishigaki, Yoshinori Nozawa, Yoshiji Yamada.   

Abstract

The purpose of the present study was to identify genetic variants which confer susceptibility to chronic kidney disease (CKD) in high- or low-risk subjects defined by conventional risk factors separately. The study population comprised 2828 Japanese individuals, including 434 subjects with CKD [estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m(2)] and 2394 controls (eGFR > or =60 ml/min/ 1.73 m(2)). The 1012 high-risk subjects had both hypertension and diabetes mellitus, and the 1816 low-risk subjects had none of these conditions. The genotypes for 296 polymorphisms of 202 candidate genes were determined. The Chi-square test, multivariable logistic regression analysis with adjustment for covariates, as well as a stepwise forward selection procedure revealed that ten different polymorphisms were associated (P<0.05) with the prevalence of CKD in high- or low-risk subjects: the -519Aright curved arrow G polymorphism of MMP1, the 1061Aright curved arrow G (Ile405Val) polymorphism of CETP, the Aright curved arrow G (Lys45Glu) polymorphism of MMP3, the -219Gright curved arrow T polymorphism of APOE, the Aright curved arrow G (Ile1205Val) polymorphism of COL3A1, the -863Cright curved arrow A polymorphism of TNF, and the 1454Cright curved arrow G (Leu125Val) polymorphism of PECAM1 in high-risk subjects; and the 1167Cright curved arrow T (Asn389Asn) polymorphism of TGFBR2, the 2386Aright curved arrow G (Ile796Val) polymorphism of SCAP, and the TAAAright curved arrow del polymorphism of PDE4D in low-risk subjects. Among these polymorphisms, the -519Aright curved arrow G polymorphism of MMP1 and the 1167Cright curved arrow T (Asn389Asn) polymorphism of TGFBR2 were most significantly associated with CKD in high- or low-risk individuals, respectively. These results suggest that polymorphisms associated with CKD may differ among high- or low-risk subjects. Stratification of subjects according to conventional risk factors may thus be important for personalized prevention of CKD based on genetic information.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19424605     DOI: 10.3892/ijmm_00000193

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  9 in total

1.  Tumor necrosis factor alpha -238 G/A and -308 G/A polymorphisms and soluble TNF-α levels in chronic kidney disease: correlation with clinical variables.

Authors:  Diana I Vázquez-Huerta; Bertha A Alvarez-Rodríguez; Jorge F Topete-Reyes; José F Muñoz-Valle; Renato Parra-Michel; Francisco Fuentes-Ramírez; María A Salazar-López; Yeminia Valle; Zyanya Reyes-Castillo; A Cruz-González; Lorena M Brennan-Bourdon; Norma Torres-Carrillo
Journal:  Int J Clin Exp Med       Date:  2014-08-15

2.  Genetic variation in phosphodiesterase (PDE) 7B in chronic lymphocytic leukemia: overview of genetic variants of cyclic nucleotide PDEs in human disease.

Authors:  Ana M Peiró; Chih-Min Tang; Fiona Murray; Lingzhi Zhang; Loren M Brown; Daisy Chou; Laura Rassenti; Thomas J Kipps; Thomas A Kipps; Paul A Insel
Journal:  J Hum Genet       Date:  2011-07-28       Impact factor: 3.172

3.  A Common APOE Polymorphism Is an Independent Risk Factor for Reduced Glomerular Filtration Rate in the Spanish RENASTUR Cohort.

Authors:  Eliecer Coto; Juan Gómez; Beatriz Tavira; Salvador Tranche; Francisco Ortega; María I Rodríguez; Emilio Sánchez; Rafael Marín; Ana I Corao; Jorge Arenas; Victoria Alvarez
Journal:  Cardiorenal Med       Date:  2013-05-16       Impact factor: 2.041

4.  Association of genetic variants with chronic kidney disease in Japanese individuals with or without hypertension or diabetes mellitus.

Authors:  Tetsuro Yoshida; Kimihiko Kato; Kiyoshi Yokoi; Mitsutoshi Oguri; Sachiro Watanabe; Norifumi Metoki; Hidemi Yoshida; Kei Satoh; Yukitoshi Aoyagi; Yoshinori Nozawa; Yoshiji Yamada
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

5.  Transforming growth factor-β receptor 2 gene polymorphisms are associated with end-stage renal disease.

Authors:  Hye-Jin Ki; Se Yun Kim; Sang Ho Lee; Ju-Young Moon; Kyung Hwan Jeong; Tae Won Lee; Chun Gyoo Ihm; Su Kang Kim; Joo-Ho Chung; Sun Woo Kang; Tae Hee Kim; Yeong-Hoon Kim; Yang Gyun Kim
Journal:  Kidney Res Clin Pract       Date:  2015-05-29

6.  PECAM-1 Leu125Val (rs688) Polymorphism and Diabetic Nephropathy in Caucasians with Type 2 Diabetes Mellitus.

Authors:  Matej Završnik; Stojan Kariž; Jana Makuc; Maja Šeruga; Ines Cilenšek; Daniel Petrovič
Journal:  Anal Cell Pathol (Amst)       Date:  2016-12-28       Impact factor: 2.916

7.  Patients with Obstructive Sleep Apnea Have Altered Levels of Four Cytokines Associated with Cardiovascular and Kidney Disease, but Near Normal Levels with Airways Therapy.

Authors:  Ye Wang; Richard B Meagher; Suresh Ambati; Huimin Cheng; Ping Ma; Bradley G Phillips
Journal:  Nat Sci Sleep       Date:  2021-03-25

8.  Integrative analysis of the plasma proteome and polygenic risk of cardiometabolic diseases.

Authors:  Scott C Ritchie; Samuel A Lambert; Matthew Arnold; Shu Mei Teo; Sol Lim; Petar Scepanovic; Jonathan Marten; Sohail Zahid; Mark Chaffin; Yingying Liu; Gad Abraham; Willem H Ouwehand; David J Roberts; Nicholas A Watkins; Brian G Drew; Anna C Calkin; Emanuele Di Angelantonio; Nicole Soranzo; Stephen Burgess; Michael Chapman; Sekar Kathiresan; Amit V Khera; John Danesh; Adam S Butterworth; Michael Inouye
Journal:  Nat Metab       Date:  2021-11-08

9.  Adverse Drug Reactions of Antihypertensives and CYP3A5*3 Polymorphism Among Chronic Kidney Disease Patients.

Authors:  Fei Yee Lee; Farida Islahudin; Abdul Halim Abdul Gafor; Hin-Seng Wong; Sunita Bavanandan; Shamin Mohd Saffian; Adyani Md Redzuan; Mohd Makmor-Bakry
Journal:  Front Pharmacol       Date:  2022-03-14       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.